ArticleJournal of clinical laboratory analysis2026
Analytical and Workflow Performance of a High-Throughput Chemiluminescent Immunoassay System in a Clinical Laboratory.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing test volumes and shorter turnaround time (TAT) requirements, particularly in acute-care settings, challenge clinical laboratories to maintain accurate immunoassay testing. High-throughput chemiluminescent immunoassay systems must therefore provide robust analytical performance and efficient workflow integration. This study evaluated the analytical performance and selected workflow characteristics of one such system under routine clinical laboratory conditions in Taiwan.
methodsThirty-six analytes were evaluated at a tertiary-care medical center. Analytical performance assessments included precision, accuracy, limit of blank (LoB), method comparison, carryover, and reference interval verification, conducted in accordance with relevant Clinical and Laboratory Standards Institute (CLSI) guidelines. Selected workflow characteristics, including pipettor consistency, low-volume precision, and time-to-first-result (TTFR) for high-sensitivity troponin I (hsTnI), beta-human chorionic gonadotropin (β-hCG), and procalcitonin (PCT)-were also assessed to evaluate operational suitability for STAT testing.
resultsAll analytes demonstrated stable performance, with within-run coefficients of variation (CV) generally below 4% and within-laboratory CV predominantly below 5%. Accuracy verification met peer-group or external quality assessment acceptance criteria for all assays. LoB values met or exceeded manufacturer specifications. Method comparison showed excellent agreement with established platforms (coefficients of determination [R
conclusionThis evaluation demonstrated that the assessed high-throughput chemiluminescent immunoassay system provided reliable analytical performance across a broad test menu and improved STAT turnaround time, supporting its routine use in hospital laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.